Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radix actinidiae chinensis is the dried root of *Actinidia arguta* (Sieb. et Zucc) Planch. ex Miq., widely used in traditional Chinese medicine and known as "tengligen" in pinyin. It is traditionally used to invigorate the spleen, dispel dampness, clear heat, detoxify, dissipate phlegm, and resolve masses. Modern pharmacology demonstrates antitumor activities, including inhibition of proliferation, migration, and invasion, and induction of autophagy and apoptosis in several cancer cell types such as colorectal, liver, and renal cancers. Key bioactive compounds include ursolic acid, quercetin, asiatic acid, and β-sitosterol. Mechanistically, radix actinidiae chinensis has been shown to induce autophagy and apoptosis through inhibition of the PI3K/AKT/mTOR and Notch signaling pathways, modulation of inflammation (e.g., TNF-α, IL-6), and effects on intestinal flora. Extracts such as ethanol extract (EERAC) have shown efficacy in reducing tumor growth in vitro and in vivo[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on radix actinidiae chinensis.